Glenmark secures marketing rights for generic Seretide inhaler in Germany

Glenmark Pharma has bagged marketing authorization for Fluticasone/Salmeterol dry powder inhaler in Germany. On launch, the DPI will be the company’s first inhalation product in that country.

The company's subsidiary Glenmark Arzneimittel GmbH has secured the authorization for Fluticasone/Salmeterol DPI. The drug is a generic version of GlaxoSmithKline’s Seretide Accuhaler. It is a combination indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD) which will be sold under the brand name Salflutin.

The company has already launched the generic version of Seretide Accuhaler in other European countries, namely, Denmark, Sweden and Norway. The DPI is commercialised through a strategic agreement with Celon Pharma S.A. (Celon) to develop and market generic Fluticasone/Salmeterol DPI in 15 European countries. The inhaler product had sales of US$ 844 million in Europe in the 12 month period ended March 2018, as per IQVIA data.

Meanwhile, at 10:04 hours, the stock of Glenmark was trading at Rs. 695.35 per share, up by 1.77 per cent on Monday, when the benchmark index BSE Sensex was at 38,105.09, down by 284.73 or 0.74 per cent.